Fairmount Funds Management LLC - 23 Mar 2026 Form 4 Insider Report for Damora Therapeutics, Inc. (DMRA)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: DMRA
Reported as of: 23 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Mar 2026, 18:03:28 UTC
Prior SEC filing: 12 Feb 2026
Next SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Damora Therapeutics, Inc. (DMRA) on 25 Mar 2026.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Damora Therapeutics, Inc. (DMRA).
1 reported transaction and 5 derivative rows are listed below.
Accepted by SEC: 25 Mar 2026, 18:03.

Change

Previous filing in this sequence was filed on 12 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (5)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Signature date: 25 Mar 2026

CIK 0001769651

Fairmount Healthcare Fund II L.P.

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P.
Signature date: 25 Mar 2026

CIK 0002091559

Fairmount Healthcare Co-Invest V L.P.

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Co-Invest V L.P.
Signature date: 25 Mar 2026

CIK 0001830177

Kiselak Tomas

Relationship: 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak
Signature date: 25 Mar 2026

CIK 0001663607

Harwin Peter Evan

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin
Signature date: 25 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +37,313
Change %
Price: $0.000000^*
Shares after: 37,313
Date: 23 Mar 2026
Ownership: By: Peter Harwin
Underlying class: Common Stock
Underlying amount: 37,313
Exercise price: $23.05
Footnotes: F1, F2

DMRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +37,313
Change %
Price: $0.000000^*
Shares after: 37,313
Date: 23 Mar 2026
Ownership: By: Peter Harwin
Underlying class: Common Stock
Underlying amount: 37,313
Exercise price: $23.05
Footnotes: F1, F2

DMRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +37,313
Change %
Price: $0.000000^*
Shares after: 37,313
Date: 23 Mar 2026
Ownership: By: Peter Harwin
Underlying class: Common Stock
Underlying amount: 37,313
Exercise price: $23.05
Footnotes: F1, F2

DMRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +37,313
Change %
Price: $0.000000^*
Shares after: 37,313
Date: 23 Mar 2026
Ownership: By: Peter Harwin
Underlying class: Common Stock
Underlying amount: 37,313
Exercise price: $23.05
Footnotes: F1, F2

DMRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +37,313
Change %
Price: $0.000000^*
Shares after: 37,313
Date: 23 Mar 2026
Ownership: By: Peter Harwin
Underlying class: Common Stock
Underlying amount: 37,313
Exercise price: $23.05
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Footnote F2

Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest V L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC remarks

Fairmount, Fund II and Co-Invest may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.